Deidra Frisbie, FNP-C

Certified Nurse Practitioner
Neurology
Accepting new patients
Call for an appointment
or

    About me

    Deidra Frisbie, FNP-C, is an advanced practice nurse for the department of Neurology at SIU Healthcare.  She is a nurse practitioner that specializes in family-focused care across the life-span.  She is board certified by the Americal Association of Nurse Practitioners (AANP).  She earned her Associate of Applied Science in Nursing from Lincoln Land Community College in 2006.  While working on a Surgical Intermediate Care Unit she earned her Bachelor of Science in Nursing degree from Benedictine University in 2010.  She continued her career on a Trauma/Surgical/Neurology Intensive Care Unit, while earning her Master of Science in Nursing degree at the University of St Francis, Joliet IL in 2016.  Deidra is currently an active member of the American Association of Nurse Practitioners, American Academy of Neurology and the American Association Critical Care Nurses.

    Gender

    Female

    Education & training

    Undergraduate Degree
    Associates Degree in Applied Sciences from Lincoln Land Community College, Springfield, IL
    Bachelor of Science in Nursing from Benedictine Univerisity, Springfield, IL
    Master of Science in Nursing from The University of St. Francis, Joliet IL

    Specialties

    Clinical locations

    Locations

    SIU Neurology Clinic

    751 N. Rutledge St. Springfield, IL 62702
    Mon - Fri: 8:00 am-4:30 pm

    Clinical trials

    Trial
    Neurology

    Portola: A Randomized Clinical Trial of Andexanet Alfa in Acute Intracranial Hemorrhage in Patients Receiving an Oral Factor XA Inhibitor

    Active not recruiting

    ANNEXa-1 (18-513): This is a randomized, multicenter clinical trial designed to determine the efficacy and safety of andexanet compared to usual care in patients presenting with acute intracerebral hemorrhage within 6 hours of symptom onset (from the baseline scan) and within 15 hours of taking an oral FXa inhibitor (from randomization). The study will use a prospective, randomized, open-label design, as it is unfeasible to blind the Investigator to the treatment assignment given the many potential therapeutic options available under usual care treatment.